Non-Hodgkin lymphoma Medical Services in China

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of malignant cancers originating from lymphoid tissue—primarily B lymphocytes (90% of cases), but also T cells or natural killer (NK) cells. Unlike Hodgkin lymphoma, NHL lacks the characteristic Reed-Sternberg cells and encompasses over 60 distinct subtypes, broadly classified as indolent (e.g., follicular lymphoma, marginal zone lymphoma), aggressive (e.g., diffuse large B-cell lymphoma—DLBCL, the most common subtype worldwide), and highly aggressive (e.g., Burkitt lymphoma). Pathogenesis involves cumulative genetic alterations—including chromosomal translocations (e.g., BCL2 in follicular lymphoma), mutations in epigenetic regulators (e.g., EZH2, CREBBP), immune evasion mechanisms, and chronic antigenic stimulation. Dysregulation of B-cell receptor signaling, NF-κB activation, and impaired tumor surveillance by T cells and NK cells further drive clonal expansion and survival of malignant lymphocytes. Epidemiologically, NHL incidence rises with age, with median diagnosis at 67 years; it accounts for ~4% of all cancers globally. In China, age-standardized incidence is approximately 5.2 per 100,000 persons annually, slightly lower than in North America or Western Europe but increasing steadily—likely due to aging populations, improved diagnostics, and environmental shifts. Key risk factors include immunosuppression (e.g., HIV infection, post-transplant immunosuppressive therapy), autoimmune disorders (e.g., Sjögren’s syndrome, rheumatoid arthritis), chronic infections (e.g., Epstein-Barr virus, Helicobacter pylori, HTLV-1), occupational exposures (e.g., pesticides, benzene), and family history of lymphoid malignancies. Notably, obesity and certain dietary patterns are emerging modifiable risks. Quality of life (QoL) impact is profound and multifaceted: patients frequently experience debilitating fatigue, night sweats, unexplained weight loss, recurrent fevers, and painless lymphadenopathy—symptoms that disrupt daily functioning, work capacity, and psychosocial well-being. Chemotherapy-induced cytopenias increase infection risk; immunotherapies may trigger immune-related adverse events (e.g., thyroiditis, pneumonitis); and long-term survivors face elevated risks of secondary malignancies, cardiovascular toxicity, and neurocognitive decline. Psychologically, anxiety about relapse, treatment uncertainty, and financial toxicity significantly impair mental health—studies report depression prevalence up to 35% among NHL patients undergoing active therapy. Supportive care integration—including palliative oncology, nutritional counseling, physical rehabilitation, and mental health services—is now recognized as essential to preserving functional status and patient-reported outcomes throughout the disease continuum.

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of malignancies arising from B-lymphocytes (90–95% of cases), T-lymphocytes, or natural killer (NK) cells. Management is highly individualized based on histologic subtype (e.g., diffuse large B-cell lymphoma [DLBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma), disease stage (Ann Arbor classification), tumor burden, patient age, performance status, comorbidities, and molecular biomarkers (e.g., MYC/BCL2/BCL6 double-hit status, CD20 expression, TP53 mutations). Treatment in the Department of Hematology integrates risk-adapted strategies across the spectrum of disease aggressiveness.

Conservative treatment—often termed 'watchful waiting' or 'active surveillance'—is standard for asymptomatic, low-tumor-burden indolent NHL subtypes such as stage I–II follicular lymphoma with minimal nodal involvement or asymptomatic small lymphocytic lymphoma (SLL). This approach avoids premature cytotoxic exposure while preserving quality of life. Patients undergo clinical assessment every 2–3 months, including physical exam, complete blood count, lactate dehydrogenase (LDH), β2-microglobulin, and imaging (e.g., contrast-enhanced CT or PET/CT) every 6–12 months. Initiation of systemic therapy is triggered by B symptoms (fever >38°C, drenching night sweats, weight loss >10% in 6 months), progressive lymphadenopathy, cytopenias due to bone marrow infiltration, organ dysfunction (e.g., renal obstruction, pulmonary compromise), or transformation to aggressive lymphoma.

Medication-based therapies constitute the cornerstone of NHL management. First-line immunochemotherapy remains R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for fit patients with DLBCL and many other aggressive subtypes. For elderly or frail patients, dose-adjusted regimens (e.g., R-miniCHOP or R-GemOx) are employed to mitigate toxicity. In FL, frontline options include rituximab monotherapy (for very low-risk elderly patients), rituximab plus bendamustine (RB), or obinutuzumab plus chlorambucil. Novel agents have transformed relapsed/refractory (R/R) disease: Bruton tyrosine kinase inhibitors (e.g., zanubrutinib, acalabrutinib) demonstrate high efficacy in MCL and CLL/SLL; lenalidomide combined with rituximab (R²) is approved for FL and MCL; polatuzumab vedotin (an anti-CD79b antibody–drug conjugate) plus bendamustine and rituximab improves outcomes in R/R DLBCL; and chimeric antigen receptor T-cell (CAR-T) therapy (e.g., axicabtagene ciloleucel, tisagenlecleucel, and relmacabtagene autoleucel—approved in China in 2021 and 2023) has achieved durable remissions in heavily pretreated aggressive B-cell lymphomas. Bispecific antibodies (e.g., glofitamab, epcoritamab) are now integrated into later-line protocols following pivotal phase II trials. Supportive medications—including granulocyte colony-stimulating factor (G-CSF) for neutropenia prophylaxis, antiviral prophylaxis (e.g., valacyclovir) during rituximab-containing regimens, and iron supplementation or erythropoietin for anemia—are routinely prescribed to optimize tolerability.

Surgical treatment plays a limited but defined role. Surgery is not indicated for primary systemic control of NHL; however, it serves critical diagnostic and palliative functions. Excisional lymph node biopsy remains the gold standard for definitive histopathologic and immunophenotypic diagnosis—core needle biopsies are insufficient for subclassification. In localized gastrointestinal MALT lymphoma associated with Helicobacter pylori, surgical resection is rarely needed; instead, antibiotic eradication is first-line. However, surgery may be required for complications such as bowel perforation, obstruction, or hemorrhage in GI lymphoma. Rarely, localized extranodal disease (e.g., solitary orbital, cutaneous, or testicular NHL) may be managed with surgical excision followed by involved-site radiotherapy (ISRT) or systemic therapy depending on risk stratification. Splenectomy retains niche utility in splenic marginal zone lymphoma with symptomatic hypersplenism or refractory cytopenias, though rituximab-based regimens have largely superseded this approach.

Treatment advantages in China reflect rapid integration of global innovations alongside domestically developed therapeutics and infrastructure strengths. China’s National Medical Products Administration (NMPA) has accelerated approvals—over 15 novel hematology drugs received NMPA approval between 2020–2024, including multiple CAR-T products (relmacabtagene autoleucel, equecabtagene autoleucel) with manufacturing timelines under 21 days at certified centers. High-volume academic hospitals (e.g., Peking University People’s Hospital, Ruijin Hospital Shanghai Jiao Tong University School of Medicine) perform over 1,200 CAR-T infusions annually, supported by standardized apheresis networks and centralized cell-processing facilities. Cost containment is achieved via inclusion of rituximab, bendamustine, and novel oral agents in the National Reimbursement Drug List (NRDL), reducing out-of-pocket expenses by up to 70%. Furthermore, China leads globally in real-world evidence generation through the China Lymphoma Working Group (CLWG) registry, enabling rapid validation of biomarker-driven algorithms (e.g., IPI and NCCN-IPI refinements for Asian populations) and optimizing risk stratification.

Recovery advice emphasizes multidimensional rehabilitation. Patients are counseled to maintain moderate physical activity (e.g., walking ≥30 minutes/day) to counteract cancer-related fatigue and improve immune surveillance. Nutrition focuses on protein-rich, anti-inflammatory foods (e.g., legumes, fatty fish, leafy greens) while avoiding raw seafood, unpasteurized dairy, and undercooked eggs during neutropenia. Vaccination status must be reviewed: influenza and pneumococcal vaccines are recommended ≥6 months post-chemotherapy; live vaccines (e.g., varicella, MMR) are contraindicated for ≥24 months after immunosuppressive therapy. Psychosocial support—including access to certified oncology psychologists and peer-led survivorship programs—is embedded in follow-up pathways. Long-term monitoring includes CBC and LDH every 3 months for first 2 years, then every 6 months for years 3–5, with annual PET/CT only if clinically indicated (not routine surveillance). Secondary malignancy screening (e.g., colonoscopy, mammography, low-dose CT lung) follows age- and risk-appropriate guidelines. Finally, fertility preservation counseling (sperm/egg cryopreservation) is offered prior to alkylator-based regimens, especially for patients <40 years. Adherence to scheduled surveillance and prompt reporting of new symptoms (e.g., persistent fever, unexplained bruising, lymph node enlargement) remain essential for early detection of relapse or late toxicities such as secondary myeloid neoplasms or cardiac dysfunction following anthracycline exposure.